Stock MEDINCELL (FR0004065605) Cotation en continu
Sector : Pharmaceuticals & Biotechnology – Indices : SBF 120, CAC ALL-TRADABLE
Last update : 30/04/2026 at 17:35:12 – Source: Euronext
📖 Codes Euronext (qu'est-ce que ça veut dire ?)
| CON | Continuous trading — séance en continu |
|---|---|
| AUC | Auction — phase de fixing |
| CAL | Call auction — appel pré-fixing |
| CLA | Closing auction — fixing de clôture |
| CLC | Close — clôture |
| CLO | Closed — séance fermée (soir, week-end) |
| TAL | Trading at last — négociation au dernier cours après fixing |
| RES | Reserved — cours réservé (volatilité hors collar). Pause auto courte, pas un signal de délisting. |
| HAL | Halted — suspension intraday courte (annonce, news). Pas un signal de délisting. |
| SUS | Suspended — sortie de cote durable. ⚠ Signal de délisting probable. |
Market summary
As of 30/04/2026, stock MEDINCELL trades at 24,68 € , with a change of -0,56 % , and a market cap of 886 M€. Reference period : April 1st, 2025 - September 30, 2025.
Price and moving averages
Technical analysis MEDINCELL
| 50-day moving average22,93 €7.63 % (above) | Pivot24,36 € |
|---|---|
| Support level20,24 €-17.99 % | Resistance level25,12 €+1.78 % |
| 1-month volatility14,77 % | Annualised volatility51,17 % |
| RSI (14d)49 Neutral | Stochastic signal (14d)Neutre |
| ATR (14d)1,17 High volatility | CMF (21d)0,01 Weak buying pressure |
| Bollinger bands (20d) Neutral | OBV (21d) Neutral (OBV stable) |
Recent news — MEDINCELL
The Montpellier-based biotech stock falls 3.55% to €23.94 at mid-session, after gaining 5.51% the previous day. The movement occurs in a sluggish Pari…
The Montpellier-based biotech's stock marks one of the strongest gains in the biotech sector on Euronext Paris in mid-afternoon trading. At 24.12 euro…
On Tuesday, April 28, 2026, shares of the Montpellier-based biotech company fell by 3.61%, closing at 22.94 euros. This decline extends a challenging …
MedInCell falls by 2.48% to 23.60 euros this Friday, amidst a significant retreat in European markets. The Montpellier-based biotech stock, still show…
The stock of the Montpellier-based biotech company fell by 3.22% this Monday during the session, to 23.48 euros, amid a significant downturn of the CA…
After soaring over 13% in a week, the stock of the biotech company from Montpellier pauses this Wednesday. MedInCell falls by 2.07% to 24.60 euros in …
Latest earnings
| Annuels 2025 | |
|---|---|
| Revenue |
25 M€
+181,4 % |
| EBITDA | -10 M€ |
| Net income |
-18 M€
+26,4 % |
| EPS (diluted) | -0,61 € |
| Net debt | 20 M€ |
Guidance
| Management commentary | Revenues are expected to accelerate in the coming years with Olanzapine LAI. |
|---|
Identified risks and opportunities
Opportunities
- Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
- UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
- AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
- Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
- Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
- Strengthened IP: additional patents (USPTO for UZEDY® until 2042; BEPO® Star US patent until 2040)
Risks
- Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
- Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
- Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
- Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
- Negative equity and continued net losses may constrain financing options
- Potential repayment obligation linked to EIB put option subject to waiver discussions
Analyses on MEDINCELL stock
No analysis has been published on this stock yet.
Frequently asked questions about MEDINCELL stock
What does the recent price action of MEDINCELL stock show?
MEDINCELL stock is currently trading around 24,68 €, down 0,56% and up +0,02% over one week.
Is MEDINCELL stock in a support or resistance zone?
Technical levels help place the stock. Support: 20,24 €. Resistance: 25,12 €.
How should the current volatility of MEDINCELL stock be interpreted?
Volatility is around 51,17%.
